Abstract-Caspase-activated DNase (CAD) is a double-strand-specific endonuclease that is responsible for the cleavage of nucleosomal spacer regions and subsequent chromatin condensation during apoptosis. Given that several endonucleases (eg, DNase I, DNase II, and Endog) have been shown to regulate pathological cardiac hypertrophy, we questioned whether CAD, which is critical for the induction of DNA fragmentation, plays a pivotal role in pressure overload-elicited cardiac hypertrophy. A CAD-knockout mouse model was generated and subjected to aortic banding for 8 weeks. The extent of cardiac hypertrophy was evaluated by echocardiography and pathological and molecular analyses. Our results demonstrated that the disruption of CAD attenuated pressure overload-induced cardiac hypertrophy, fibrosis, and cardiac dysfunction. Conversely, transgenic mice with cardiac-specific overexpression of CAD showed an aggravated cardiac hypertrophic response to chronic pressure overload. Mechanistically, we discovered that the expression and activation of mitogen-activated protein kinase-extracellular signal-regulated kinase 1/2 was significantly reduced in the CADknockout hearts compared with the control hearts; however, they were greatly increased in the CAD-overexpressing hearts after aortic banding. Similar results were observed in ex vivo cultured neonatal rat cardiomyocytes after treatment with angiotensin II for 48 hours. These data indicate that CAD functions as a necessary modulator of the hypertrophic response by regulating the mitogen-activated protein kinase-extracellular signal-regulated kinase 1/2 signaling pathway in the heart. Our study suggests that CAD might be a novel target for the treatment of pathological cardiac hypertrophy and heart failure. (Hypertension. 2015;65:871-881.
C ardiac hypertrophy is a response of the myocardium to an increased workload and is characterized by an increase in myocardial mass and an accumulation of extracellular matrix. [1] [2] [3] Although cardiac hypertrophy might initially represent an adaptive response of the myocardium, it frequently progresses to ventricular dilatation and heart failure. Heart failure is a debilitating disease with high morbidity and mortality rates, and its prevalence is increasing. [4] [5] [6] [7] Although hypertrophy was first described more than a century ago and several studies have identified the signal transduction pathways that promote hypertrophic responses, the mechanisms that regulate these pathways have not been clearly elucidated. 8 A better understanding of these regulatory mechanisms in cardiac myocytes might lead to novel strategies for suppressing cardiac hypertrophy.
Caspase-activated DNase (CAD), also known as DNA fragmentation factor 40 kDa, is a double-strand-specific endonuclease responsible for the cleavage of nucleosomal spacer regions and subsequent chromatin condensation during apoptosis. [9] [10] [11] In growing and nonapoptotic cells, CAD is maintained as an inactive complex combined with its inhibitor (inhibitor of CAD, also known as DNA fragmentation factor-45) and is predominantly localized in the cytoplasm. [12] [13] [14] When cells are induced to die by apoptotic stimuli, such as Fas ligand or the kinase inhibitor staurosporine, caspases are activated. The activated caspases, predominantly caspase-3, cause CAD to be released from the CAD/inhibitor of CAD complex and subsequently transferred into the nucleus, where it is spontaneously activated. 15, 16 After activation, unobstructed CAD configures into a scissor-like dimer and cleaves genomic DNA with minimal sequence specificity. This CAD-mediated process is an important mechanism underlying caspase-3-dependent apoptotic nuclear alterations. [17] [18] [19] CAD not only induces DNA fragmentation during apoptosis but also functions as a prerequisite for inducing cell differentiation. 20 The functions of CAD are similar to those of other endonucleases, such as DNase I, DNase II, and Endog, which are important modulators of apoptosis and cardiac hypertrophy. Investigations have revealed that CAD interacts with several transcriptional regulators of cell proliferation, including HSP70 (heat shock protein 70), HSP40 (heat shock protein 40), and HMGB1 (high mobility group box chromosomal protein 1), which play a critical role in cardiac hypertrophy and heart failure. [21] [22] [23] [24] [25] [26] These observations ensure that CAD is an attractive target for therapeutic intervention to treat or prevent cardiac hypertrophy and heart failure.
In the present study, we first discovered that CAD was downregulated in heart samples collected from human patients with dilated cardiomyopathy (DCM) and in samples collected from animals after aortic banding (AB). Second, using CADknockout (CAD−/−) mice and cardiac-specific transgenic (TG) mice, we demonstrated for the first time that CAD−/− mice are protected from developing cardiac hypertrophy and fibrosis by blocking mitogen-activated protein kinase (MEK)-extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathway, whereas TG mice with constitutive cardiac expression of human CAD displayed the opposite phenotype in response to AB, suggesting a crucial role for CAD in modulating cardiac remodeling.
Materials and Methods
The animal protocol was approved by the Animal Care and Use Committee of Union Hospital of Huazhong University of Science and Technology. An expanded Methods section is available in the onlineonly Data Supplement and includes detailed information regarding the following: reagents, human heart samples, experimental animal models and AB surgery, echocardiography and hemodynamic evaluations, histological analysis, cardiomyocyte culture and infection with recombinant adenoviral vectors, assessment of apoptosis, immunofluorescence staining, Western blot analysis, quantitative real-time polymerase chain reaction, and statistical analysis.
Results

CAD Expression Is Downregulated in Human Pathological Hearts and Murine Hypertrophic Hearts
To explore the potential role of CAD in the development of cardiac hypertrophy and heart failure, we first examined whether the CAD expression levels were altered in pathological hearts. Using Western blotting to investigate the correlation between CAD and cardiac hypertrophy, we first examined CAD expression in the left ventricle of patients with DCM undergoing heart transplantation secondary to end-stage heart failure. Our data revealed that the protein levels of CAD were reduced by ≈63%, whereas myosin heavy chain (β-MHC) and atrial natriuretic factor (ANP)-2 markers of hypertrophic hearts-were markedly increased compared with their levels in healthy donor hearts ( Figure 1A ), which was consistent with the results of human hypertrophic cardiomyopathy and ischemic cardiomyopathy hearts ( Figure S1 in the onlineonly Data Supplement). In an experimental mouse model of AB-induced cardiac hypertrophy (evidenced by elevation of β-MHC and ANP levels), CAD expression was downregulated by ≈48% in mouse hearts 4 weeks after AB and by ≈87% at week 8 after AB compared with its level in sham-operated hearts ( Figure 1B ). In the cultured neonatal rat cardiomyocytes (NRCMs) treated with angiotensin II (Ang II, 1 μmol/L) or phenylephrine (100 μmol/L) for 48 hours to induce hypertrophy, the CAD protein levels were significantly reduced by 55% (Ang II) and 51% (phenylephrine), respectively ( Figure 1C ). These results indicate that the protein levels of CAD are markedly decreased in human DCM/hypertrophic cardiomyopathy/ischemic cardiomyopathy hearts and in pressure overload-induced hypertrophic mouse hearts as well as in vitro Ang II/phenylephrine-treated cardiomyocytes, suggesting that CAD might be involved in the development of cardiac hypertrophy.
Absence of CAD Attenuates Pressure OverloadInduced Cardiac Hypertrophy
After determining the alterations of CAD levels in diseased hearts, we next sought to examine whether decreased CAD levels in the heart would influence the development of cardiac hypertrophy and failure. We used a global knockout of CAD (CAD−/−) mouse model (RIKEN [Rikagaku Kenkyusho/ Institute of Physical and Chemical Research], Figure 2A ) and subjected the mice to AB surgery or sham operations for 8 weeks, and CAD−/− mice did not affect blood pressure before or 1 week after AB ( Figure S2A ). It is important to note that under basal conditions, the CAD−/− mice did not show any pathological/physiological alterations in cardiac structure or function (Table S1 ). Relative to the AB-treated wild-type (CAD+/+) mice, the myocardial hypertrophic response was significantly blocked in CAD−/− mice after 8 weeks of AB, as shown by direct examination of the gross heart, hematoxylin-eosin, wheat germ agglutinin-fluorescein isothiocyanate staining, and the cardiomyocyte cross-sectional area ( Figure 2B and 2C) . The ratios of heart weight/body weight, heart weight/tibia length, and lung weight/body weight were significantly decreased in the CAD−/− mice compared with the CAD+/+ mice after 8 weeks of AB ( Figure 2D ). The echocardiography measurements indicated that these changes were accompanied by improved cardiac dilation and reduced dysfunction in the CAD−/− versus CAD+/+ mice ( Figure 2E , Figure S3A , Figure S4A , and Table S2 ). Consistent with these morphological alterations, the mRNA levels of several hypertrophy markers, including ANP, brain natriuretic peptide, and β-MHC, were much lower in the CAD−/− mice than those of CAD+/+ mice after 8 weeks of AB ( Figure 2F ).
Fibrosis is a classical feature of pathological cardiac hypertrophy and is characterized by the accumulation of collagen in the heart. To further define the effect of CAD deficiency on maladaptive cardiac remodeling, we examined the effect of CAD on cardiac fibrosis. The extent of fibrosis was quantified based on the collagen volume by visualizing the total amount of collagen present in the interstitial and perivascular spaces. Our results showed that interstitial and perivascular fibrosis were dramatically increased in the CAD+/+ hearts subjected to chronic AB, but these types of fibrosis were markedly limited in the CAD−/− hearts ( Figure 2G and 2H) . Finally, we measured the synthesis of collagen by analyzing the mRNA expression levels of fibrotic markers (eg, connective tissue growth factor, collagen I, and collagen III). Our results consistently revealed a decreased fibrotic response in the CAD−/− mice ( Figure 2I ). Collectively, these data indicate that the deletion of CAD suppresses pressure overload-induced cardiac remodeling, suggesting that the reduced CAD expression observed in human DCM hearts might play a compensatory role in guarding against the effects of various stress conditions.
Overexpression of CAD Aggravates Pressure Overload-Induced Cardiac Hypertrophy
We next addressed whether elevated levels of CAD in the heart had any effect on the development of cardiac hypertrophy and failure. To examine this issue, TG mice with cardiac-specific overexpression of human CAD were generated using the α-MHC promoter ( Figure S5A ). Four germ lines of CAD TG mice were established and verified by western blotting ( Figure  S5B ). The expression of mouse endogenous CAD was not affected by the overexpression of the human CAD gene ( Figure  S5B ), and transgenic CAD was specifically expressed in the heart ( Figure S5C ). Under basal conditions, all of the CAD-TG mice were healthy and showed no apparent cardiac morphological or pathological abnormalities ( Figure S3B , Figure S4B , and Table S1 ). We selected transgenic line 1, which expressed the highest levels of CAD, for further experiments. CAD TG mice and their wild-type littermates (referred to as nontransgenic [NTG]) were subjected to AB surgery or a sham operation and examined after 4 weeks. In contrast to the results observed in the CAD−/− mice compared with the NTG mice, the CAD TG mice showed pathological cardiac hypertrophy induced by chronic AB, as evidenced by an increase in cardiomyocyte size (gross heart, hematoxylin-eosin, wheat germ agglutininfluorescein isothiocyanate staining, and the cross-sectional area; Figure 3A and 3B) and higher ratios of heart weight/body weight, heart weight/tibia length, and lung weight/body weight ( Figure 3C ). The cardiac structure and function, as assessed by left ventricular end-diastolic diameter, left ventricular end-systolic diameter, and left ventricular fractional shortening, were significantly impaired ( Figure 3D and Table S3 ). Additionally, markers of cardiac hypertrophy (ANP, brain natriuretic peptide, and β-MHC) were dramatically upregulated in the TG mice compared with the NTG mice ( Figure 3E ). We next assessed the effect of CAD overexpression on AB-triggered cardiac fibrosis. The histological analysis and the analyses of fibrotic markers consistently demonstrated an increased fibrotic response in the AB-operated TG mice compared with the AB-treated NTG mice ( Figure 3F-3H ). These gain-of-function data indicate that the overexpression of CAD exaggerates cardiac hypertrophy and fibrosis in response to chronic pressure overload.
CAD Aggravates Angiotensin II-Induced Cardiomyocyte Hypertrophy In Vitro
We determined the functional contribution of CAD on cardiomyocyte hypertrophy in vitro using primary cultured NRCMs in a well-controlled experimental setting. NRCMs were infected with AdshCAD to knockdown CAD or with AdCAD to overexpress CAD ( Figure 4A ). Subsequently, these infected cardiomyocytes were exposed to Ang II (1 μmol/L) or to PBS as a control for 48 hours, followed by immunostaining with α-actinin to measure the cell size. Under basal conditions, neither AdshCAD nor AdCAD affected the size of the cultured NRCMs compared with the control AdshRNA and AdGFP cells ( Figure 4C and 4D) . In response to Ang II-induced cell hypertrophy, AdshCAD significantly reduced the cross-sectional area by 25.2% compared with the AdshRNA-infected controls ( Figure 4B and 4C), whereas Ang II-induced cell hypertrophy was greatly enhanced by 30.5% in the AdCAD-treated NRCMs compared with the AdGFP cells ( Figure 4B and 4D) . Accordingly, the Ang II-induced expression of hypertrophic hallmarks (ANP and β-MHC) was dramatically suppressed in the AdshCAD-infected cardiomyocytes ( Figure 4E ), whereas it was remarkably enhanced in the AdCAD-infected NRCMs compared with the controls ( Figure 4F ). Our ex vivo data and in vivo results suggest that the downregulation of CAD mitigates pathological cardiac hypertrophy, whereas the upregulation of CAD promotes pathological cardiac hypertrophy.
Effect of CAD on the Mitogen-Activated Protein Kinase Signaling Pathway
The above results suggest that CAD might aggravate pressure overload-induced cardiac hypertrophy. However, the underlying mechanism by which CAD regulates the hypertrophic response remains unknown. Given that the mitogen-activated protein kinase (MAPK) signaling pathway has been previously shown to play an important role in cardiac hypertrophy, we first examined whether CAD affected the AB-induced MAPK signaling response. 27, 28 As expected, we observed that MEK1/2, ERK1/2, c-Jun N-terminal kinase 1/2 (JNK1/2), and p38 were significantly phosphorylated in AB mice. However, the phosphorylation of MEK1/2 and ERK1/2 was almost completely inhibited in the CAD−/− hearts compared with the CAD+/+ hearts, whereas JNK1/2 and p38 were not significantly affected ( Figure 5A) . Conversely, the overexpression of CAD dramatically elevated the levels of MEK1/2 and ERK1/2 phosphorylation compared with the levels observed in NTGs after AB ( Figure 5B ). Although AKT signaling plays a crucial role in the regulation of cardiac remodeling, we did not observe any differences in AKT activation between the groups (CAD−/− versus CAD+/+ and TG versus NTG, data not shown). These data suggest that the regulation of CAD in hypertrophy might be mediated by MEK-ERK1/2 rather than by the AKT signaling pathway.
To further confirm the regulatory effect of CAD on MEK-ERK1/2 signaling, we infected NRCMs with AdshCAD, AdshRNA, AdCAD, or AdGFP and exposed the cells to 1 μmol/L Ang II for 48 hours. The western blotting results showed that the Ang II-triggered activation of MEK1/2 and ERK1/2 was significantly attenuated by infection with AdshCAD; however, this activation was markedly increased by infection with AdCAD ( Figure 5C and 5D) . Additional in vitro experiments were performed to examine whether MEK-ERK1/2 signaling has a causative role in CAD-mediated cardiac hypertrophy. We pretreated NRCMs with U0126 (an MEK inhibitor that prevents ERK1/2 phosphorylation) for 1 hour and then treated the cells with Ang II for 48 hours after infection with AdGFP or AdCAD for 24 hours. As expected, increased CAD levels led to pronounced hypertrophy induced by Ang II as assessed by surface area measurements. This response was strongly blunted in the U0126-treated samples compared with the samples treated with Ang II alone ( Figure  S6A and S6B). The Ang II-induced expression of hypertrophic hallmarks (ANP and β-MHC) was dramatically suppressed by pretreatment with U0126 ( Figure S6C and S6D ). These results demonstrate that the detrimental role of CAD in pathological cardiac hypertrophy is largely associated with the regulation of MEK-ERK1/2 signaling. Furthermore, the preinhibition of MEK-ERK1/2 signaling could inhibit the prohypertrophic effects of CAD in pressure-overloaded hearts.
CAD Regulates Smad Signaling Pathway
Pathological cardiac hypertrophy is accompanied by interstitial and perivascular fibrosis, and approaches to prevent collagen deposition in the heart have been limited to date. Transforming growth factor-β/Smad is an important signaling pathway involved in the development of cardiac fibrosis. To examine the molecular mechanisms of CAD in collagen synthesis, we assessed the regulatory role of CAD on Smad cascade activation. Our results showed that AB-induced increased levels of Smad 2/3 phosphorylation and nuclear translocation were significantly attenuated in CAD−/− mice compared with CAD+/+ hearts ( Figure 6A ). Importantly, CAD TG mice induced higher levels of Smad 2/3 phosphorylation and nuclear translocation compared with that of NTG control mice ( Figure 6B ). These findings indicate that the detrimental role of CAD in pathological cardiac hypertrophy is dependent, at least in part associated with Smad signaling pathway.
Effect of CAD on Apoptosis
It is well known that apoptosis is involved in pathological cardiac remodeling. Because CAD has been shown to play a vital role in apoptosis, we examined whether the role of CAD in regulating hypertrophy was related to its proapoptotic effect in the AB-induced hypertrophic model. Myocardial tissue sections were subjected to terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining to detect apoptotic cells. TUNEL-positive nuclei were present in the control mice subjected to AB, whereas their number was significantly decreased in the CAD−/− mice and markedly increased in the TG mice ( Figure 7A and 7B) . We examined the signaling pathways related to AB-induced apoptosis in the heart. Caspase-3 is a key mediator of apoptosis, and its activation leads to DNA injury and subsequent apoptotic cell death. The activation and cleavage of caspase-3 induced by AB was modest in the control hearts and rarely observed in the CAD−/− hearts; however, the activity and cleavage of Caspase-3 was increased considerably in the TG hearts. In response to AB, the expression of Bax, which functions as a proapoptotic protein, was increased, whereas the expression of the antiapoptotic protein Bcl-2 was decreased. As predicted, the ratio of Bax to Bcl-2 was remarkably lower in the CAD−/− mice and was significantly higher in the TG mice after AB (Figure 7C 
Discussion
In the case of pathological cardiac hypertrophy, increased heart size is initially a compensatory mechanism; however, sustained hypertrophy could ultimately lead to a decline in left ventricular function and is an independent risk factor for heart failure. [4] [5] [6] [7] It is therefore necessary to clarify the mechanism underlying cardiac hypertrophy and to identify key targets for treatment. In our study, we found that CAD expression was downregulated in human pathological hearts and in mouse hypertrophic hearts, suggesting that CAD might be involved in the processes of cardiac hypertrophy and failure. However, this result is in sharp contrast to which Birks et al 29 have found, the myocardial CAD levels were significantly increased in patients with DCM, compared with their levels in healthy donor hearts. As we known, different drugs used, different severities of DCM, different causes of DCM, or even different races were the reasons for different gene expression level. Thus, different CAD expression patterns between the study by Birks et al 29 and our study may be the synthetic effect of all the above reasons. Importantly, clarifying the exact mechanism that regulates CAD expression needs further study. Using the loss-of-function and gain-of-function approaches, we discovered that CAD was a necessary modulator in the development of pathological cardiac hypertrophy. The disruption of CAD in the heart profoundly ameliorates cardiac hypertrophy and dysfunction following chronic pressure overload, whereas TG mice with cardiac-specific overexpression of CAD displayed an exaggerated AB-induced hypertrophic response. Moreover, our study indicates that CAD mediates AB-induced cardiac hypertrophy, at least in part, by regulating the MEK-ERK1/2 signaling pathway. Furthermore, CAD develops its proapoptotic potential by promoting myocyte apoptotic cell death through decreased the expression of Bcl-2 and increased the expression of Bax and caspase-3. The results of our study suggest for the first time that the blockade of CAD could be an effective strategy for the treatment of pathological cardiac hypertrophy.
The possible mechanisms by which CAD regulates cardiac hypertrophy remain unclear. It is generally accepted that biomechanical stress induced by pressure overload triggers a variety of signal transduction molecules and pathways that regulate the hypertrophic growth of cardiac myocytes. Numerous studies have demonstrated that the MAPK signaling pathway plays a critical role in the pathogenesis of cardiac hypertrophy and heart failure. The MAPK cascade comprises a sequence of successive kinases, including ERKs, JNKs, and p38, and is triggered in cardiac myocytes by stress stimuli. After this cascade is activated, ERKs, JNKs, and p38 phosphorylate a wide array of intracellular targets, resulting in the reprogramming of cardiac gene expression. [30] [31] [32] [33] To examine the molecular mechanisms involved in the ability of CAD to regulate cardiac hypertrophy, we investigated the activation status of the MAPK pathway in our hypertrophic models. We observed that the activation of MEK1/2 and ERK1/2 was blocked by the loss of CAD; however, it was enhanced by cardiac CAD overexpression in response to chronic pressure overload.
Moreover, the CAD overexpression-induced aggravation of cardiac remodeling was mitigated by a MEK-ERK1/2 inhibitor, indicating that the MEK-ERK1/2 signaling pathway is critically involved in the prohypertrophic effects of CAD. However, CAD did not affect the phosphorylation of JNK1/2 and p38. Given that the AKT signaling cascade plays a crucial role in the regulation of cardiac remodeling, we examined the status of AKT signaling in our hypertrophic models. We found that CAD did not influence the increased phosphorylation levels of AKT induced by AB. These findings suggest that the detrimental role of CAD in pathological cardiac hypertrophy is at least partially mediated through the MEK-ERK1/2 signaling pathway. However, further experiments are needed to determine the molecular mechanism by which CAD regulates the MEK-ERK1/2 pathway.
Cardiac fibrosis is an additional classic feature of pathological hypertrophy and is characterized by the expansion of the extracellular matrix caused by the accumulation of collagen. 34, 35 Our study demonstrated that CAD ablation significantly inhibits cardiac fibrosis and attenuates the expression of several fibrotic mediators induced by chronic pressure overload, whereas overexpression of CAD augments the fibrotic response. These findings suggest that the detrimental role of CAD in pathological cardiac hypertrophy is dependent, at least in part associated with Smad signaling pathway.
Cardiac myocyte apoptosis plays an important role in the transition of cardiac hypertrophy to heart failure. 36 Our experimental findings revealed a correlation between an increase in the frequency of apoptosis and the extent of cardiac hypertrophy. Consistent with previous reports, 9-12 the disruption of CAD in the heart markedly decreased the number of apoptotic cells in response to pressure overload. Furthermore, we found that the attenuation of myocardial apoptosis induced by CAD ablation was associated with the increased expression of Bcl-2 and the decreased expression of Bax and caspase-3. The overexpression of CAD significantly increased the number of apoptotic cells subjected to AB in conjunction with lower Bcl-2 expression and increased Bax and caspase-3 expression. The effects of CAD on these signaling molecules might explain the protection from apoptosis observed in the CAD knockout hearts as well as the destructive effects in the CAD TG hearts in pathological cardiac hypertrophy.
In conclusion, this investigation is the first study to define a role for CAD in cardiac hypertrophy. Our findings indicate that knockdown/knockout of CAD mitigates the development of pathological cardiac hypertrophy. Conversely, upregulation of CAD aggravates pressure overload-induced cardiac hypertrophy and heart failure. The mechanism underlying the protective role of CAD in the development of cardiac hypertrophy seems to be related to the MEK-ERK1/2 signaling pathway. These findings provide novel insights into the molecular mechanisms underlying pathological cardiac hypertrophy. Based on these findings, CAD might represent a new therapeutic target for suppressing the onset of cardiac hypertrophy and failure.
Perspectives
The current study provides in vivo and in vitro evidence that CAD, a double-strand-specific endonuclease, functions as a pivotal regulator in cardiac hypertrophy. The absence of CAD inhibits pressure overload-induced cardiac hypertrophy, fibrosis, and cardiac dysfunction, whereas the cardiacspecific overexpression of CAD promotes the hypertrophic response by regulation of the MEK-ERK1/2 signaling pathway. These findings suggest that CAD might be a novel therapeutic target for preventing cardiac hypertrophy and heart failure. 23 24 Or Correspondence to 25 Xiao-Dong Zhang, PhD The following primary antibodies were used in our experiments: Anti-CAD (sc30061), 3 anti-β-MHC (sc53090) and anti-ANP (sc20158) were purchased from Santa Cruz Peroxidase-conjugated secondary antibodies (Jackson Immuno Research Laboratories, 12 West Grove, PA, USA) were utilized for the visualization of primary antibody binding. Aortic banding (AB) was conducted as described previously [6] [7] [8] . Adequate analyzed to compare the heart weight/body weight (HW/BW, mg/g), lung 12 weight/body weight (LW/BW, mg/g), and heart weight/tibia length (HW/TL, mg/mm) 13 ratios between the KO and WT mice and between the TG and NTG mice. 14 15 Echocardiography and hemodynamic evaluations 16 Echocardiography was performed in mice anesthetized with 1.5% isoflurane using a expression levels were normalized to GAPDH on the same nitrocellulose membrane. 6 The total mRNA was extracted from the ventricles and primary cells using the 7 TRIzol reagent (Invitrogen), and cDNA was synthesized using oligo (dT) primers 8 with the Transcriptor First Strand cDNA Synthesis Kit (Roche). The PCR 9 amplifications were quantified using SYBR Green PCR Master Mix (Applied 10 Biosystems) and normalized to GAPDH gene expression.
12
Statistical analysis 13 The data are represented as the mean ± SD. Student's two-tailed t-test was used to 14 compare the means of two groups of samples, and two-way analysis of variance with 15 general linear model procedures using a univariate approach was applied for more 16 than two groups. A value of P<0.05 was considered a statistically significant 17 difference. All of the statistical analysis were performed with SPSS software (version 18 11.0, SPSS Inc.). Tables   1   Table S1 Anatomic and Echocardiographic Analysis in 10-Week Old Mice. 8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26 
